Search

Ben-David, U., B. Siranosian, G. Ha, H. Tang, Y. Oren, K. Hinohara, C. A. Strathdee, et al. 2018. “Genetic and Transcriptional Evolution Alters Cancer Cell Line Drug Response”. Nature 560: 325-30.

Boehm, J. S., and T. R. Golub. 2015. “An Ecosystem of Cancer Cell Line Factories to Support a Cancer Dependency Map”. Nat Rev Genet 16: 373-4.

Bourquin, J. P., A. Subramanian, C. Langebrake, D. Reinhardt, O. Bernard, P. Ballerini, A. Baruchel, et al. 2006. “Identification of Distinct Molecular Phenotypes in Acute Megakaryoblastic Leukemia by Gene Expression Profiling”. Proc Natl Acad Sci U S A 103: 3339-44.

Bradner, J. E., R. Mak, S. K. Tanguturi, R. Mazitschek, S. J. Haggarty, K. Ross, C. Y. Chang, et al. 2010. “Chemical Genetic Strategy Identifies Histone Deacetylase 1 (HDAC1) and HDAC2 As Therapeutic Targets in Sickle Cell Disease”. Proc Natl Acad Sci U S A 107: 12617-22.

Cheung, H. W., J. Du, J. S. Boehm, F. He, B. A. Weir, X. Wang, M. Butaney, et al. 2011. “Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers”. Cancer Discov 1: 608-25.

Coller, H. A., C. Grandori, P. Tamayo, T. Colbert, E. S. Lander, R. N. Eisenman, and T. R. Golub. 2000. “Expression Analysis With Oligonucleotide Microarrays Reveals That MYC Regulates Genes Involved in Growth, Cell Cycle, Signaling, and Adhesion”. Proc Natl Acad Sci U S A 97: 3260-5.

Ebert, B. L., and T. R. Golub. 2004. “Genomic Approaches to Hematologic Malignancies”. Blood 104: 923-32.

Feuerhake, F., J. L. Kutok, S. Monti, W. Chen, A. S. LaCasce, G. Cattoretti, P. Kurtin, et al. 2005. “NFkappaB Activity, Function, and Target-Gene Signatures in Primary Mediastinal Large B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma Subtypes”. Blood 106: 1392-9.

Golub, T. R. 1997. “TEL Gene Rearrangements in Myeloid Malignancy”. Hematol Oncol Clin North Am 11: 1207-20.

Golub, T. R. 2001. “Genomic Approaches to the Pathogenesis of Hematologic Malignancy”. Curr Opin Hematol 8: 252-61.